The year-over-year FVIII expression levels following valoctocogene roxaparvovec administration demonstrate declining expression with the most recent data presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress [78]. The gene discussed is F8; the disease is hemophilia.